• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.纯化的C3b灭活剂对C3b灭活剂缺乏症患者体内补体介导功能的恢复作用。
J Clin Invest. 1975 Mar;55(3):668-72. doi: 10.1172/JCI107975.
2
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.对一名易感染患者体内C3代谢异常的体内和体外研究。
J Clin Invest. 1970 Nov;49(11):1975-85. doi: 10.1172/JCI106417.
3
The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.酵母聚糖与正常及C4缺陷豚鼠血清中备解素系统的反应。含B因子的C3和C5裂解多亚基酶的证实,以及经典补体途径对其形成的加速作用。
J Immunol. 1973 Nov;111(5):1389-400.
4
Cyanate as an inactivator of complement proteins.氰酸盐作为补体蛋白的一种灭活剂。
J Immunol. 1975 Dec;115(6):1558-65.
5
Metabolism of C3 and factor B in patients with congenital factor I deficiency.先天性因子I缺乏症患者中C3和因子B的代谢
J Clin Lab Immunol. 1990 Feb;31(2):59-67.
6
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.风湿性疾病中的C3b灭活剂。通过放射免疫扩散法以及对备解素途径C3转化酶形成的抑制作用进行测量。
J Clin Invest. 1976 Jun;57(6):1554-63. doi: 10.1172/JCI108426.
7
Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.人类补体第五成分的遗传性缺陷。I. 临床、免疫化学及家系研究。
J Clin Invest. 1976 Jun;57(6):1626-34. doi: 10.1172/JCI108433.
8
Complete absence of the third component of complement in man.人类补体第三成分完全缺失。
J Clin Invest. 1975 Sep;56(3):703-10. doi: 10.1172/JCI108141.
9
Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.通过备解素途径在人血清中裂解第三补体成分(C3)并生成致痉肽C3a:ε-氨基己酸抑制和增强作用的证明
J Immunol. 1975 Feb;114(2 Pt 1):671-7.
10
Homozygous human C3 deficiency. The role of C3 in antibody production, C-1s-induced vasopermeability, and cobra venom-induced passive hemolysis.纯合子人类C3缺乏症。C3在抗体产生、C1s诱导的血管通透性和眼镜蛇毒诱导的被动溶血中的作用。
J Clin Invest. 1976 Jan;57(1):222-9. doi: 10.1172/JCI108263.

引用本文的文献

1
Physiology and pathology of the C3 amplification cycle: A retrospective.C3 扩增循环的生理学和病理学:回顾。
Immunol Rev. 2023 Jan;313(1):217-224. doi: 10.1111/imr.13165. Epub 2022 Nov 21.
2
Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated Diseases.动物模型对补体介导的疾病的替代途径和扩增环(AP/AL)驱动的机制理解的贡献。
Immunol Rev. 2023 Jan;313(1):194-216. doi: 10.1111/imr.13141. Epub 2022 Oct 6.
3
Classical and Non-classical Presentations of Complement Factor I Deficiency: Two Contrasting Cases Diagnosed via Genetic and Genomic Methods.经典和非经典补体因子 I 缺乏症表现:通过遗传和基因组方法诊断的两个对比病例。
Front Immunol. 2019 Jun 7;10:1150. doi: 10.3389/fimmu.2019.01150. eCollection 2019.
4
Properdin homeostasis requires turnover of the alternative complement pathway.补体固有途径的稳态需要替代途径的转换。
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19444-8. doi: 10.1073/pnas.1006608107. Epub 2010 Oct 25.
5
Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.部分补体因子I缺乏症中的反复感染:对一个巴西家族三代人的评估
Clin Exp Immunol. 2006 Feb;143(2):297-304. doi: 10.1111/j.1365-2249.2005.02988.x.
6
Complement deficiency.补体缺陷
Clin Rev Allergy Immunol. 2000 Oct;19(2):83-108. doi: 10.1385/CRIAI:19:2:83.
7
Complement-activating ability of leucocytes from patients with complement factor I deficiency.补体因子I缺乏症患者白细胞的补体激活能力。
Immunology. 1997 Jul;91(3):486-92. doi: 10.1046/j.1365-2567.1997.00273.x.
8
The molecular basis of hereditary complement factor I deficiency.遗传性补体因子I缺乏症的分子基础。
J Clin Invest. 1996 Feb 15;97(4):925-33. doi: 10.1172/JCI118515.
9
C3b inactivator deficiency with immune complex manifestations.伴有免疫复合物表现的C3b灭活因子缺乏症。
Clin Exp Immunol. 1982 Jan;47(1):197-205.
10
Editorial: Complement activation and disease.社论:补体激活与疾病
Br Med J. 1976 Feb 21;1(6007):416-7. doi: 10.1136/bmj.1.6007.416.

本文引用的文献

1
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.阿尔珀·C·A、罗森·F·S:对正常受试者和患者体内人补体C3行为的研究。
J Clin Invest. 1967 Dec;46(12):2021-34. doi: 10.1172/JCI105691.
2
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.在含有抗体的琼脂糖凝胶中通过电泳对蛋白质进行定量估计。
Anal Biochem. 1966 Apr;15(1):45-52. doi: 10.1016/0003-2697(66)90246-6.
3
A molecular concept of immune cytolysis.免疫细胞溶解的分子概念。
Arch Pathol. 1966 Sep;82(3):205-17.
4
Deficiency of C3 inactivator in man.人类C3灭活因子缺乏症。
J Immunol. 1971 Jul;107(1):19-27.
5
Leukin, a bactericidal agent from rabbit polymorphonuclear leucocytes.白细胞素,一种来自兔多形核白细胞的杀菌剂。
Nature. 1967 Nov 25;216(5117):806-8. doi: 10.1038/216806a0.
6
Formation and function of a complex of the C3 proactivator with a protein from cobra venom.补体3前活化剂与眼镜蛇毒蛋白复合物的形成及功能
J Exp Med. 1973 Feb 1;137(2):451-60. doi: 10.1084/jem.137.2.451.
7
The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.富含甘氨酸的糖蛋白与备解素系统中的B因子以及人血清眼镜蛇因子结合蛋白的关系。
J Exp Med. 1973 Feb 1;137(2):424-37. doi: 10.1084/jem.137.2.424.
8
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).替代补体途径:参与眼镜蛇毒因子(CoVF)激活补体第三成分(C3)的相关因子。
J Immunol. 1973 Jan;110(1):128-38.
9
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).补体激活的替代途径。C3及其灭活剂(KAF)的作用。
Immunology. 1973 Feb;24(2):259-75.
10
Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phagocytic disorders.采用分光光度法检测对感染患者和吞噬细胞疾病患者的调理素及白细胞功能进行评估。
Blood. 1973 Jul;42(1):121-30.

纯化的C3b灭活剂对C3b灭活剂缺乏症患者体内补体介导功能的恢复作用。

Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

作者信息

Ziegler J B, Alper C A, Rosen R S, Lachmann P J, Sherington L

出版信息

J Clin Invest. 1975 Mar;55(3):668-72. doi: 10.1172/JCI107975.

DOI:10.1172/JCI107975
PMID:1117072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC301796/
Abstract

In a patient with lifelong increased susceptibility to infection and multiple abnormalities in complement-mediated functions, the infusion of normal plasma had been seen to produce a prolonged partial correction of serum abnormalities. It was subsequently shown that the patient was genetically deficient in the C3b inactivator and that immunochemical depletion of C3b inactivator from normal serum resulted in abnormalities similar to those found in the patient's serum, including alternative pathway C3 activation. Highly purified C3b inactivator was obtained from the euglobulin fraction of normal human serum, sterilized by filtration, and infused intravenously. Partial or complete correction of almost all the known serum abnormalities was obtained. C3b almost disappeared from the serum within 4-5 h, as did Factor C activity. Native C3, C5, and serum hemolytic activity rose to normal or near-normal levels over 4 days and were sustained for another week. Factor B, properdin, opsonic activity, and bactericidal activity reached a level at least two-five times that found before the infusion within 24 h and fell over the next 5 days. These observations prove the primary role of C3b inactivator deficiency in the patient's disease and demonstrate clearly the curcial role in vivo of C3b inactivator in modulating alternative pathway activity.

摘要

在一名终身易患感染且补体介导功能存在多种异常的患者中,输注正常血浆可使血清异常得到部分纠正且持续时间延长。随后发现该患者在基因上缺乏C3b灭活剂,并且从正常血清中免疫化学去除C3b灭活剂会导致与患者血清中发现的异常相似的情况,包括替代途径C3激活。从正常人血清的优球蛋白组分中获得高度纯化的C3b灭活剂,经过滤灭菌后静脉输注。几乎所有已知的血清异常均得到部分或完全纠正。C3b在4 - 5小时内几乎从血清中消失,C因子活性也随之消失。天然C3、C5和血清溶血活性在4天内升至正常或接近正常水平,并持续一周。B因子、备解素、调理活性和杀菌活性在24小时内达到至少比输注前高两到五倍的水平,并在接下来的5天内下降。这些观察结果证明了C3b灭活剂缺乏在该患者疾病中的主要作用,并清楚地表明了C3b灭活剂在体内调节替代途径活性中的关键作用。